PharmaShots | Incisive News in 3 Shots

Subscribe Now

Pruritus

Cara and Vifor's Korsuva (difelikefalin) Receive the US FDA's Approval for the Treatment of Moderate-to-Severe Pruritus Due to CKD in Patients with Hemodialysis

Cara and Vifor's Korsuva (difelikefalin) Receive the US FDA's Approval for the Treatment of Moderate-to-Severe Pruritus Due to CKD...

August 25, 2021

Kiniksa's Vixarelimab Receives the US FDA's Breakthrough Therapy Designation to Treat Pruritus Associated with Prurigo Nodularis

Kiniksa's Vixarelimab Receives the US FDA's Breakthrough Therapy Designation to Treat Pruritus Associated with Prurigo Nodularis

November 16, 2020

Chugai's Nemolizumab Receives the US FDA's Breakthrough Therapy Designation to Treat Pruritus Associated with Prurigo Nodularis

Chugai's Nemolizumab Receives the US FDA's Breakthrough Therapy Designation to Treat Pruritus Associated with Prurigo Nodularis

December 9, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us